Synthesis and biodistribution of a novel <Superscript>99m</Superscript>Tc nitrido dithiocarbamate complex containing ether group as a potential myocardial and brain imaging agent

In the present study, a novel ^99mTc nitrido dithiocarbamate complex containing ether group, the bis(2-ethoxyethyl dithiocarbamato) nitrido ^99mTc complex ^99mTcN(EOEDTC)₂ has been synthesized by the reduction of ^99mTcO₄ ⁻ into [^99mTcN]²⁺ with stannous chloride in the presence of succinic dihydrazide and propylenediamine tetraacetic acid, followed by the addition of the corresponding dithiocarbamate ligand. The radiochemical purity of the complex was over 90% as measured by thin layer chromatography (TLC). In vitro studies showed that the complex possessed good stability. Its partition coefficient indicated that it was lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the complex accumulated in the heart and brain with high initial uptake, suggesting the complex may lead to a further development of the radiopharmaceutical as a heart and brain perfusion tracer.     

Synthesis and biodistribution of <Superscript>99m</Superscript>TcN-isopentyl xanthate as a potential myocardial perfusion imaging agent

A novel ^99mTc nitrido xanthate complex ^99mTcN(IPEXT)₂ (IPEXT: isopentyl xanthate) has been synthesized by the reduction of ^99mTcO₄ ⁻ into [^99mTcN]²⁺ with stannous chloride in the presence of succinic dihydrazide and propylenediamine tetraacetic acid, followed by the addition of the corresponding xanthate ligand. The radiochemical purity of the complex was over 90% as measured by thin layer chromatography (TLC). No decomposition of the complex at room temperature was observed over a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the ^99mTcN(IPEXT)₂ complex accumulated in the heart with high uptake. The heart uptake (%IDg) was 8.00% at 5-minute post-injection, but the heart/lung, heart/liver and heart/blood ratios were not high, thereby, restricting the use of the complex as a good myocardial imaging agent.     

一种新型脑灌注显像剂99mTcN-CPDTC的制备及生物分布

目前临床上广泛使用的99mTc脑灌注显像剂是以［99mTcO］3+核为中心核的配合物99mTc-乙撑双半胱氨酸二乙酯(99mTc-ECD)和99mTc-六甲基丙撑二胺肟(99mTc-HMPAO). ［99mTc≡N］2+核由于具有较高的化学稳定性以及用99mTcN核代替99mTcO核后其配合物的生物分布性能发生了较大的改变［1～3］, 因此研究含99mTcN核的配合物成为寻找新型放射性药物的一条有效途径.     

Synthesis of 99m TcN(IPDTC)2 and its biodistribution in mice

In order to seek a new class of brain perfusion imaging agent containing[ ^99m TcN]²+ core, the bis(N-isopropyl dithiocarbamato)nitrido technetium-99m complex [ ^99m TcN(IPDTC)₂ ] (IPDTC:N-isopropyldithiocarbamato) has been synthesized through a simple and efficient method,which can be utilized for the preparation of a radiopharmaceutical througha lyophilized formulation. The radiochemical purity of the complex was over90% determined by thin layer chromatography. No decomposition of the complexwas observed at room temperature over a period of 12 hours. Its partitioncoefficient indicated that it was a good lipophilic complex. Biodistributionin mice demonstrated that the complex was significantly retained into thebrain. The brain uptake (ID%/g) was 3.90, 2.67 and 1.54 and the brain/bloodratios were 1.26, 1.06 and 0.85 at 5, 30 and 60-minute post-injection, respectively.The results showed that the complex may lead to a further development of theradiopharmaceutical as a brain perfusion tracer.     

99mTc-DMSA complex preparation: the effect of pH and tin(II) chloride amount on reaction

Labelling of meso-2,3-dimercaptosuccinic acid (DMSA) with technetium-99m was reinvestigated. Dependence of the ^99mTc-DMSA complex formation on the molar ratio of DMSA:reducing agent (SnCl₂·2H₂O) and pH was studied. Five different types of ^99mTc-DMSA complexes were determined. Especially three different complexes were established in the clinically used and prepared DMSA kit labelled with ^99mTc under alkaline condition. This radiopharmaceutical is used as imaging agent of the primary medullary carcinoma in the thyroid gland and different metastasis types. The existence of all complexes was observed by paper chromatography, paper electrophoresis and high performance liquid chromatography.     

Synthesis and biodistribution of 99mTcN(PDTC)2as a potential brain imaging agent

The preparation of the bis(N-propyl dithiocarbamato) nitrido technetium-99m complex ^99mTcN(PDTC)₂ (PDTC: N-propyl dithiocarbamato) was carried out as a freeze-dried formulation, through a simple procedure involving the initial of ^99mTcO_4- with succinic dihydrazide in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexant, followed by the addition of the ligand sodium salt of N-propyl dithiocarbamate to afford the final product. The radiochemical purity of the complex was over 90%, as measured by thin layer chromatography. No decomposition of the complex at room temperature was observed over a period of 12 hours. Its partition coefficient indicated that it was a good lipophilic complex. Biodistribution in mice showed that the complex accumulated in the brain with high uptake. The brain uptake (ID%/g) was 5.07 and the brain/blood ratio 1.34 at 5-minute post-injection. This suggested a potential usefulness of the complex as a brain perfusion imaging agent. This revised version was published online in July 2006 with corrections to the Cover Date.     

99mTcN核标记的新型心肌灌注显像剂的研究

通过配体交换反应制备了[99mTcN(PNP5)(DEDC)]+和[99mTcN(PNP5)(DPODC)]+两种新配合物, 其放化纯度均大于90%. 生物性能研究结果表明: 两种配合物在小鼠心肌中的初始摄取高, 肝、肺等非靶组织清除快, 靶/非靶比高, 有利于早期心肌显像. 其中, [99mTcN(PNP5)(DEDC)]+在小鼠中的性质较优, 且其在狗体内的性质接近99mTc-tetrofosmin, 有望成为一种新型心肌灌注显像剂.     

Synthesis and biological evaluation of novel 99mTc-oxo and 99mTc-nitrido complexes with phenylalanine dithiocarbamate for tumor imaging

In this study, phenylalanine dithiocarbamate (PHEDTC) ligand was successfully synthesized and then radiolabeled with [^99mTcO]³⁺ core and [^99mTc≡N]²⁺ core to produce ^99mTcO–PHEDTC and ^99mTcN–PHEDTC, respectively. Both complexes were prepared with high radiochemical purity and had good stability. The partition coefficient results showed they were hydrophilic, while ^99mTcN–PHEDTC was more hydrophilic than ^99mTcO–PHEDTC. The biodistribution study in mice bearing S 180 tumor showed that ^99mTcO–PHEDTC and ^99mTcN–PHEDTC had high tumor uptake at 2 h post-injection, 1.91 and 1.21, respectively. The good uptake and retention in tumor together with favorable tumor-to-muscle ratios make them promising candidates for further evaluation as potential tumor imaging agents.     

The identity confirmation of 99gTc-DMSA complexes by using NMR and HPLC–MS/MS methods

The analyses of ^99gTc-DMSA complexes prepared under alkali and acidic reactions were reported. Modern analytical, separation and spectral methods such as NMR (¹H-NMR, ¹³C-NMR, APT, COSY and HSQC) and Q-TOF HPLC–MS/MS system with ESI were employed to determine the identity and characterization of the products. The structure of ^99gTc(V)DMSA was clearly confirmed and its fragmentation path in negative and positive ionisation mode was suggested. The effect of ascorbic acid and new alternative labelling with the use of NH ₄ ^99g TcOCl₄ was examined. Surprisingly, ^99gTc(III)DMSA complex was not formed under acidic reaction conditions. ^99gTc(V)DMSA complex was the main reaction product under both experimental conditions. This result suggests the key role of ^99g/99mTc concentration during the process of radiopharmaceuticals preparation.     

Synthesis of a bis-(N-butyl-dithiocarbamato)-nitrido 99mTc complex: A potential new brain imaging agent

The bis(N-butyl dithiocarbamato) nitrido ^99mTc complex [^99mTcN(BDTC)₂] (BDTC: N-butyl dithiocarbamato) has been synthesized through a ligand-exchange reaction. The two-step procedure consisted of an initial reaction of ^99mTcO₄ ⁻ with succinic dihydrazide (SDH) in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexing agent, and subsequent addition of sodium salt of N-butyl dithiocarbamate. The radiochemical purity of the complex was over 90%, as measured by thin layer chromatography. No decomposition of the complex at room temperature was observed over a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the complex accumulated in the brain with high uptake. The brain/blood ratio was 1.58, 1.67 and 1.20 at 5, 30 and 60-minute post-injection, respectively, suggesting this compound would be a potential cerebral imaging agent.     

In vitro incorporation studies of 99mTc–alendronate sodium at different bone cell lines

Bisphosphonates can be labeled with Technetium-99m (^99mTc) and are used for bone imaging because of their good localization in the skeleton and rapid clearance from soft tissues. Over the last decades bone scintigraphy has been used extensively in the evaluation of oncological patients to provide information about the sites of bone lesions, their prognosis and the effectiveness of therapy by showing the sequential changes in tracer uptake. Since the lesion visualization and lesion/bone ratio are important utilities for a bone scanning radiopharmaceutic; in this study incorporation of ^99mTc labeled alendronate sodium (^99mTc–ALD) was evaluated in U₂OS (human bone osteosarcoma) and NCI-H209 (human bone carcinoma) cell lines. ALD was directly labeled by ^99mTc, radiochemical purity and stability of the complex were analyzed by radioactive thin layer chromatography and radioactive high performance liquid chromatography studies. For cell incorporation study, NCI-H209 and U₂OS cell lines were used with standard cell culture methods. The six well plates were used for all experiments and the integrity of each cell monolayer was checked by measuring its transepithelial electrical resistance (TEER) with an epithelial voltammeter. Results confirmed that ALD was successfully radiolabeled with ^99mTc. ^99mTc–ALD incorporated with NCI-H209 and U₂OS cells. The uptake percentages of ^99mTc–ALD in NCI-H209 and U₂OS cell lines were found significantly different. Since ^99mTc–ALD highly uptake in cancer cell line, the results demonstrated that radiolabeled ALD may be a promising agent for bone cancer diagnosis.     

A Freeze Dried Kit for 99mTc(V) Dimercaptosuccinic Acid

^99mTc pentavalent dimercaptosuccinic acid [^99mTc(V) DMSA], a useful agent for imaging thyroid medullary carcinoma and other tumors can be reliably prepared by addition of Na^99mTcO₄ to a freeze-dried mixture of DMSA and Sn (2:1 molar ratio). The radiochemical purity, stability and animal bio-distribution behaviour is similar to that of the agent made by addition of NaHCO₃ to DMSA (III) renal imaging freeze-dried kit.     

99mTcN(PNP5)(NOEt)]+新型心肌灌注显像剂研究

以氯化亚锡为还原剂,SDH(丁二酰二酰肼)为供氮体,经配体交换反应得到[^99mTcN(PNP5)·(NOEt)]⁺,通过TLC和HPLC分析,其放化纯度大于90%.该标记物是一种体外稳定性良好的阳离子配合物,在小鼠和狗体内的心肌初始摄取量高,滞留好,肝和肺等非靶组织清除快,有利于早期心肌显像,有望成为一种新型的心肌灌注显像剂.     

[99mTcN(PNP5)(NOEt)]+: A novel potential myocardial perfusion imaging agent

Summary The asymmetrical [^99mTcN(PNP5)(NOEt)]⁺heterocomplex containing a terminal technetium-nitrogen multiple bond coordinated to the diphosphine ligand (PNP5) and the dithiocarbamate ligand (NOEt), was prepared through ligand exchange reaction. Its radiochemical purity was over 90% as measured by TLC and HPLC. Biodistribution in mice and SPECT imaging in dog were studied. The results showed that [^99mTcN(PNP5)(NOEt)]⁺ possessed high myocardial uptake and good retention, and high target to non-target ratios, suggesting that it may be a potential myocardial perfusion imaging agent.     

Synthesis and biodistribution of 99mTcN(CHIPDTC)2 as a potential myocardial perfusion imaging agent

The bis(N-cyclohexyl, N-isopropyl dithiocarbamato) nitrido technetium-99m complex [^99mTcN(CHIPDTC)₂] (CHIPDTC: N-cyclohexyl, N-isopropyl dithiocarbamato) has been synthesized through a ligand-exchange reaction. The two-step procedure involved the initial reaction of ^99mTcO₄ ^- with succinic dihydrazide (SDH) in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexant, followed by the addition of the sodium salt of N-cyclohexyl, N-isopropyl dithiocarbamate. The radiochemical purity (RCP) of the complex was 96±2% as measured by thin layer chromatography (TLC). No decomposition of the complex at room temperature (r. t.) was observed within a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed that the complex was neutral. Biodistribution in mice indicated that the complex accumulated in the heart with high uptake and good retention. The heart/blood, heart/lung ratio was 6.28 and 1.35, respectively, at 60-minute post-injection, suggesting that it would be a potential myocardial perfusion imaging agent.     

Synthesis and biodistribution of a novel <Superscript>99m</Superscript>Tc-DMSA-metronidazole ester as a potential tumor hypoxia imaging agent

The dimercaptosuccinic acid metronidazole ester (DMSAMe) was synthesized and radiolabeled with ^99mTc to form the ^99mTc-DMSAMe complex in high yield. The radiochemical purity of the ^99mTc-DMSAMe complex was over 90%, as measured by TLC and by HPLC, without any notable decomposition at room temperature over a period of 6 h. Its partition coefficient indicated that it was a lipophilic complex. The tumor cell experiment and the biodistribution in mice bearing S 180 tumor showed that the ^99mTc-DMSAMe complex had a certain hypoxic selectivity and accumulated in the tumor with high uptake and good retention. The tumor/blood and tumor/muscle ratios increased with time, suggesting it would be a possible tumor hypoxia imaging agent.     

Synthesis and biological evaluation of <Superscript>99m</Superscript>Tc-DHPM complex: a potential new radiopharmaceutical for lung imaging studies

In the recent years interests on dihydropyrimidinone and their analogues have increased potentially due to their wide range of pharmacological/biological activities. Synthesis, radiolabeling with technetium-99 m (^99mTc) and biological evaluation of 5-etoxycarbonyl-4-phenyl-6-methyl-3,4-dihydro-(1H)-pyrimidine-2-one (DHPM) were studied in this present work. After synthesis complexation of DHPM with ^99mTc was carried out using stannous chloride as the reducing agent. The complex (^99mTc-DHPM) was characterized by thin layer chromatography, radio-HPLC technique and determination of partition co-efficient. Radiochemical stability and particle size distribution of the complex were also measured. Biodistribution/scintigraphy studies were performed in rats and rabbits to evaluate the pharmacological characteristics of this complex. The radiochemical purity of the complex was over 95% as studied by thin layer chromatography and radio-HPLC. It was stable over 24 h at room temperature. Its partition coefficient indicated that it was a lipophilic complex. According to the European Pharmacopeia, >80% of ^99mTc labeled radiopharmaceutical (^99mTc-MAA) in the size range 10–50 μm, must be accumulated in the lungs 15 min after intravenous administration. In this study >85% of the ^99mTc-DHPM complex in the average size of 40 μm. Biodistribution studies of ^99mTc-DHPM in rat revealed that the complex accumulated in the lung with high uptake and good retention after intravenous administration. Scintigraphic studies in rabbit also revealed that most of the administered radiolabeled complex was accumulated in the lungs and after 1 h slowly excreted through the renal system. The lung uptake (ID%/g) was 10.12, 9.67, 8.60 and 5.01 and the lung/liver ratio was 7.49, 2.88, 2.62 and 1.87 at 2, 15, 30 and 60 min post-injection, respectively. These results suggested that ^99mTc-DHPM could be suitable as a potential lung perfusion imaging agent. Further studies with ^99mTc-DHPM and its derivatives are warranted to develop new ^99mTc-labeled imaging agents for clinical applications.     

Substituent effect on redox potential of nitrido technetium complexes with Schiff base ligand: Theoretical calculations

Theoretical calculations based on the density functional theory (DFT) were performed to understand the effect of substituents on the molecular and electronic structures of technetium nitrido complexes with salen type Schiff base ligands. Optimized structures of these complexes are square pyramidal. The electron density on a Tc atom of the complex with electron withdrawing substituents is lower than that of the complex with electron donating substituents. The HOMO energy is lower in the complex with electron withdrawing substituents than that in the complex with electron donating substituents. The charge on Tc atoms is a good measure that reflects the redox potential of [TcN(L)] complex.     

Synthesis and biodistribution of 99mTc(CO)3-DMSA-MIBI in mice

Mixed ligand fac-tricarbonyl complex of [^99mTc(CO)₃-DMSA-MIBI] has been prepared starting from the precursor [^99mTc(OH₂)₃(CO)₃]⁺. The complex can be obtained in good yield and purity in a two-step procedure by first attaching meso-2,3-dimercaptosuccinic acid (DMSA, HOOCCH(SH)CH(SH)COOH) with [^99mTc(OH₂)₃(CO)₃]⁺, followed by addition of MIBI [tetrakis-2-methoxyisobutylisonitrile (CH₃OC(CH₃)₂CH₂-N≡C) copper(I) tetrafluoroborate] solution. The complex was characterized by TLC and HPLC and was studied by means of octanol-water partition coefficient, electrophoresis, stability in vitro, and normal mice experiment. Biodistribution in mice demonstrated that the complex showed higher myocardial uptake after 0.5-hour p.i. The ratios of heart/liver (%ID/g) in the case of ^99mTc(CO)₃-DMSA-MIBI was higher (1.88) than that observed in case of ^99mTc-MIBI¹ (0.93) after 0.5-hour p.i. (P<0.05). Results showed that the complex may be developed to a novel myocardial perfusion-imaging agent.     

Synthesis and biological evaluation of a novel <Superscript>99m</Superscript>Tc complex of HYNIC-conjugated aminomethylenediphosphonate as a potential bone imaging agent

A conjugate of 6-hydrazinopyridine-3-carboxylic acid (HYNIC) with aminomethylenediphosphonic acid (AMDP) was synthesized through a multiple-step reaction. HYNIC–AMDP could be labeled easily and efficiently with ^99mTc using N-(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine (tricine) as coligand to form the ^99mTc–HYNIC–AMDP complex in high yield (> 95%). Its partition coefficient indicated that it was a good hydrophilic complex. The biodistribution studies of ^99mTc–HYNIC–AMDP in normal ICR mice showed that this complex had high bone uptake and low or negligible accumulation in non-target organs. As compared with ^99mTc–MDP, ^99mTc–HYNIC–AMDP had a higher bone uptake and the ratios of bone/blood and bone/muscle at early time after injection, suggesting that it could be potentially useful for bone imaging at an earlier time after injection according to further investigations of the biological behavior of this complex.